Journal of Clinical Medicine

Journal Browser

► Journal Browser

Clinical Advances in Glaucoma, 2nd Edition

Share This Special Issue

Special Issue Editor

Special Issue Information

Dear colleagues,

We are pleased to announce the 2nd Edition of the Special Issue Clinical Advances in Glaucoma (https://www.mdpi.com/journal/jcm/special_issues/GO39UMU3B7).

Glaucoma is a chronic and progressive optic neuropathy disease, resulting in the deterioration of visual function. Intraocular pressure increase is not the only symptom responsible for the development and progression of glaucoma, although it is the only one on which effective therapeutic action can be carried out.

Recently, many advances in the diagnosis and treatment of glaucoma have been described, and structural glaucoma diagnostic advances with optical coherence tomography have improved its diagnostic performance. The recent COVID-19 outbreak has led to advances in the development of telemedicine and even iPad perimetric testing. One of the technological advances that has contributed to the increased interest in the influence of the vascular factor on the development of glaucoma is optical coherence tomography with angiography or optical coherence angiotomography. With this non-invasive tool, circumpapillary, papillar and macular vessel density have been shown to be lower in glaucoma patients.

On the other hand, while Goldmann applanation tonometry is still the gold standard for pressure measurements, new tonometers based on different working principles are gradually being introduced into routine clinical practice.

Currently, further progress is necessary in new diagnostic techniques and telemedicine applied to the disease.

Dr. Carmen Dora Méndez-Hernández
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.

Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.

Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.

External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.

e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

10 pages, 541 KiB

Open AccessArticle

Near Add Power of Glaucoma Patients with Early Presbyopia

by Masahiko Ayaki and Kazuo Ichikawa

J. Clin. Med. 2024, 13(19), 5675; https://doi.org/10.3390/jcm13195675 - 24 Sep 2024

Viewed by 560

Abstract

Purpose: Glaucoma medication may accelerate the progression of presbyopia. The aim of this study was to compare presbyopia between controls and patients with glaucoma in their 40s. Methods: This was a cross-sectional study of bilateral phakic participants aged between 40 and 49, which included controls (n = 114, mean age 46.1 ± 2.7 y) and patients with primary open-angle glaucoma (n = 105, 46.4 ± 2.7 y) who had been using FP receptor agonists, beta blockers, and carbonic anhydrase inhibitors for at least six months. We compared the near add power between the two groups. Results: The mean near add power and the prevalence of symptomatic presbyopia (near add power ≥ 1.50 D) were 1.16 ± 0.74 D and 42.1% for controls and 1.77 ± 0.71 D (p < 0.01) and 79.0% (p < 0.01) for glaucoma patients, respectively. The odds ratio (OR) and confidence interval for symptomatic presbyopia were associated with age (1.36, 1.21–1.52), ganglion cell complex thickness (0.96, 0.94–0.99), presence of glaucoma (6.19, 3.13–12.23), and number of glaucoma medications (4.26, 2.42–7.43). Among medications, only FP receptor agonists (5.79, 2.68–12.32) produced significant results. Survival analysis showed that glaucoma patients reached the threshold of a near add power of +1.50 D significantly sooner than controls (p < 0.05; log-rank test). Conclusions: Glaucoma patients, especially those using FP receptor agonists, had higher near add power than controls. Full article

(This article belongs to the Special Issue Clinical Advances in Glaucoma, 2nd Edition)

► Show Figures

Figure 1

16 pages, 3056 KiB

Open AccessArticle

Evaluating the Safety and Efficacy of a Novel Glaucoma Drainage Device in High-Risk Adult Glaucoma Patients: A One-Year Pilot Study

by Faisal Ahmed, Eduardo Normando, Syed Ahmed, Simrun Virdee and Ahmed Al-Nahrawy

J. Clin. Med. 2024, 13(17), 4996; https://doi.org/10.3390/jcm13174996 - 23 Aug 2024

Cited by 1 | Viewed by 953

Abstract

Background: We report on the 12-month safety and efficacy outcomes of a new non-valved glaucoma drainage device, the eyePlate-300 (Rheon Medical, Lausanne, Switzerland), in managing refractory glaucoma. Methods: A retrospective review was conducted on consecutive patients over 18 who underwent glaucoma drainage device (GDD) surgery with the eyePlate-300 after a single glaucoma consultation between February 2020 and April 2021, with at least 12 months of documented post-op follow-up. Results: A total of 16 eyes from 15 patients were included. Complete success was observed in 47% of patients and overall success in 83%. The mean IOP decreased from 31.5 mm Hg to 10.7 mm Hg (67% reduction from baseline), and the number of IOP-lowering drops was reduced from 3.1 to 0.7 at one year. The mean BCVA remained stable. No additional IOP-lowering surgeries were required, and no severe sight-threatening complications were noted. Conclusions: The initial one-year results suggest that the eyePlate could be a safe and effective device for reducing IOP in an ethnically diverse refractory glaucoma population. Further follow-up is necessary to determine the long-term safety and efficacy. Full article

(This article belongs to the Special Issue Clinical Advances in Glaucoma, 2nd Edition)

► Show Figures

Journal Menu

Journal Browser

Clinical Advances in Glaucoma, 2nd Edition

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Related Special Issue

Published Papers (2 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI